Ponatinib (AP-24534) is a third-generation tyrosine kinase inhibitor (TKI) that addresses the clinically concerning BCR-ABL(T3151) mutation seen in chronic myeloid leukemia (CML). This drug was originally developed as AP...
TAK-875 is a free fatty acid receptor 1 (FEA1R/GPR40) agonist, the first in this novel class of antidiabetic agents to enter clinical development. It is a glucose-dependent insulinotropic agent, with a mechanism of actio...
TG-101348 is an orally available, small-molecule inhibitor of the tyrosine-protein kinase JAK2 (Janus kinase 2, JAK-2) that is under investigation for the treatment of myelofibrosis. Myelofibrosis and the related myelopr...
Trastuzumub emtansine (T-DM1) is a novel antibody-drug conjugate. The conjugate is comprised of the antibody trastuzurnab, which is directed against the receptor tyrosine-protein kinase erbB-2 (HERZ), a derivative of the...
A number of gene-based vectors have been tested to deliver HIV-1 antigens to immune systems as vaccines. While many challenges remain, a number of promising results hove recently been observed to re-energize the HIV vacc...
One of the hallmarks of autoimmune diabetes is the presence of adaptive responses directed against neuroendocrine proteins, such as glutamic acid decarboxylase (GAD). While GAD is widely distributed in neuroendocrine tis...